Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Other financing activities (2016 - 2022)

Cumberland Pharmaceuticals (CPIX) has disclosed Other financing activities for 13 consecutive years, with -$370464.0 as the latest value for Q1 2022.

  • Quarterly Other financing activities fell 232.3% to -$370464.0 in Q1 2022 from the year-ago period, while the trailing twelve-month figure was -$650484.0 through Mar 2022, down 147.35% year-over-year, with the annual reading at $1.0 million for FY2019, 1121.21% up from the prior year.
  • Other financing activities hit -$370464.0 in Q1 2022 for Cumberland Pharmaceuticals, up from -$632646.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $1.0 million in Q3 2019 to a low of -$806390.0 in Q4 2020.
  • Historically, Other financing activities has averaged $70521.5 across 5 years, with a median of $131692.0 in 2020.
  • Biggest YoY gain for Other financing activities was 1057.1% in 2019; the steepest drop was 422.44% in 2019.
  • Year by year, Other financing activities stood at $81886.0 in 2018, then skyrocketed by 1057.1% to $947500.0 in 2019, then crashed by 185.11% to -$806390.0 in 2020, then increased by 21.55% to -$632646.0 in 2021, then surged by 41.44% to -$370464.0 in 2022.
  • Business Quant data shows Other financing activities for CPIX at -$370464.0 in Q1 2022, -$632646.0 in Q4 2021, and $452536.0 in Q3 2021.